Visioneering Technologies Inc (VTI) has enrolled 144 children for its international clinical trial that studied its NaturalVue multifocal contact lenses for myopia management.
Protect (PROgressive myopia Treatment Evaluation for NaturalVue multifocal Contact lens Trial) was a multi-centre, randomised, double-masked clinical trial in Canada, the US, Hong Kong and Singapore.
It has enrolled 144 healthy, near-sighted children aged from seven to 13 years of age whose current prescription was between -0.75D and -5.00D. VTI expected results from Protect would corroborate its real-world data that showed ‘a significant positive impact’ of NaturalVue for the management of myopia.
Dr Ashley Tuan, chief medical officer at VTI, said: ‘We greatly appreciate the efforts of those independent eye care professionals serving as principal investigators in this study and their commitment to providing the highest quality evidence of the effectiveness of this outstanding product. I look forward to sharing interim one-year results in late 2023.’
Register now to continue reading
Thank you for visiting Optician Online. Register now to access up to 10 news and opinion articles a month.
Register
Already have an account? Sign in here